OrganaBio opened a local PBMC processing and cryopreservation lab in San Diego to compress the time from leukapheresis to frozen product for autologous cell therapies. The workflow is designed to isolate and cryopreserve PBMCs within three to four hours of collection rather than shipping live material across long supply chains. OrganaBio reported average PBMC viability around 99.1% and recovery above 2.9 million cells per milliliter, supported by standardized operating procedures and a unified quality system across sites. For sponsors, the reported reduction in processing window aims to limit functional degradation of starting immune cells, a known risk factor for variable downstream results in autologous immunotherapies.